A5063389336- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- HIV, Drug Use, Sexual Risk
- Multiple and Secondary Primary Cancers
- HIV/AIDS Research and Interventions
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Sex work and related issues
- Gastric Cancer Management and Outcomes
- Cutaneous Melanoma Detection and Management
- Metastasis and carcinoma case studies
- CAR-T cell therapy research
- Adolescent Sexual and Reproductive Health
- Immunotherapy and Immune Responses
- Asymmetric Synthesis and Catalysis
- Metal-Organic Frameworks: Synthesis and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Gastrointestinal Tumor Research and Treatment
- Substance Abuse Treatment and Outcomes
- Digestive system and related health
- Covalent Organic Framework Applications
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
The University of Texas MD Anderson Cancer Center
2019-2025
Vassar College
2008-2024
Yale University
2013
Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied the neoadjuvant space.
Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness anti-interleukin-6 receptor (anti-IL-6R) therapy for irAEs. Methods We performed a retrospective multicenter study evaluating patients diagnosed de novo irAEs flare pre-existing autoimmune disease following ICI were treated...
Abstract Immune checkpoint inhibition (CPI) for metastatic colorectal cancer (mCRC) with deficient mismatch repair (dMMR) demonstrates high clinical activity that appears durable, but the impact of CPI on pathological tumor response is unknown. In this retrospective analysis, our objective was to assess and outcomes in dMMR mCRC patients treated prior surgical resection primary and/or tumor. Among 121 advanced at 2 institutions between November 2016 December 2018, 14 underwent surgery....
256 Background: Immunotherapy has shown the ability to induce a high rate of pathologic and clinical complete response in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC). The role circulating tumor DNA (ctDNA) as prognostic biomarker for survival who receive non-operative management (NOM) is unknown. Among enrolled phase II trial (NCT04082572) that evaluated efficacy pembrolizumab locally advanced dMMR/MSI-H solid tumors, we...
Abstract Background: While detection of circulating tumor DNA (ctDNA) weeks after surgery is linked to recurrence for other solid tumors, the optimal time point ctDNA assessment as a prognostic biomarker following chemoradiation anal cancer undefined. Methods: Patients with stages I-III treated between 12/2020-5/2024 were evaluated HPV status at baseline, end chemoradiation, and during surveillance using droplet digital PCR assay targeting E6 E7 oncogenes 13 oncogenic types. Median...
Abstract The Immune Checkpoint Inhibitors (ICIs) have significantly changed treatment approaches for patients with various cancers, including melanoma, in advanced and/or adjuvant settings. Acral melanomas are rare but aggressive clinical subtype of and there is an urgent need to improve care acral aimed at the ICIs. While biomarker studies drug discoveries cutaneous melanoma achieved substantial progress, little known about either what prognostic markers how predict response ICI modalities....
Background Peru's HIV epidemic is concentrated among men who have sex with (MSM). The contribution of alcohol use disorders (AUDs) to known high-risk behaviors associated transmission in this context has not been well characterized. Methods Between June and October 2011, 5,148 sexually active MSM were recruited using convenience sampling five cities participate a cross-sectional bio-behavioral survey. Five sexual criteria previously incident infection setting selected priori as the dependent...
Background Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs alloHCT is increased risk graft-versus-host disease (GVHD). We analyzed association between GVHD prophylaxis and frequency in patients who had received ICI therapy alloHCT. Methods A retrospective study was performed 21 with acute myeloid leukemia (n=16) or myelodysplastic syndromes (n=5)...
Immune checkpoint inhibitors improve survival in patients with mismatch repair deficiency/microsatellite instability-high (MSI-H) colorectal cancer. The recurrence outcomes following discontinuation of immunotherapy after prolonged disease control have not been definitively reported large series. Records from advanced MSI-H cancer University Texas - MD Anderson Cancer Center who received between 2014 and 2022 stopped clinical benefit were reviewed. Median progression-free overall estimated....
2520 Background: Pembrolizumab (Pembro), anti-PD1 therapy, is FDA approved for refractory microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) advanced/metastatic solid tumors. The robust activity of therapy in these tumors argues a neoadjuvant organ-sparing approach. However, the role monotherapy setting unknown. Methods: This phase 2 open-label, single center trial (NCT04082572) MSI-H/dMMR non-metastatic with localized unresectable or risk resectable (defined as ≥ 20%...
3524 Background: Markers of systemic inflammation including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), and monocyte-to-lymphocyte (LMR) are prognostic in patients with metastatic colorectal cancer receiving chemotherapy. The presence liver metastases has also been hypothesized to modulate response immunotherapy. In this study, we assess the role these markers microsatellite high (MSI-H)/deficient mismatch repair (dMMR) tumors immunotherapy for or unresectable (CRC)....
145 Background: Deficiency in mismatch repair or high microsatellite instability (dMMR/MSI-H), occurring approximately 20% of all colorectal cancer (CRC) cases and 4% metastatic CRC (mCRC), predicts clinical benefit immune checkpoint blockade (ICB). With response rates about 50% mCRC higher localized cases, ICB is providing durable even cure a meaningful portion cases. However, further understanding those patients who progress treatment options following progression are needed. Methods: A...
LBA3557 Background: Identifying non-responders to expensive salvage therapies with modest benefits and substantial treatment related adverse events (TRAEs) (e.g. regorafenib [Reg] or TAS102 [Tas] in mCRC) is key precision care. Retrospective studies suggest that ctDNA changes at timepoints (4-10 weeks [wks] into therapy) before radiographic assessment may predict outcomes. However, prospective assessing early are lacking clinical utility remains uncertain. Methods: TACT-D a randomized study...
10602 Background: Universal germline testing (UGT) in solid cancer patients increases the detection of pathogenic variants (PGVs) over guideline-based testing. There is a rising incidence young onset (YO) gastrointestinal (GI) cancers (50 years and under). PGV rates this population can be as high 20%, highlighting benefit UGT. Underserved populations experience significant disparities The primary aim study to evaluate among with GI large safety net identify barriers facilitators order...
3612 Background: Neoadjuvant immunotherapy (IO) has shown promise as a potential non-surgical, curative therapy in pts with localized dMMR/MSI-H CRC. However, response assessment to IO is challenging due difficulty measuring luminal tumors, the invasive nature of endoscopy, and known discordance between these modalities. ctDNA may serve an important, novel marker this population. We evaluated pre-treatment clearance their association pathologic complete (pCR) CRC treated IO. Methods:...
3610 Background: Early data suggests that immunotherapy (IO) for localized colorectal cancer (CRC) is associated with high rates of pathologic complete response (pCR) and durable remission. This study aims to characterize endoscopic, imaging, pathological outcomes among patients who received IO CRC. Methods: was a single-institution retrospective analysis MSI-H CRC at least one cycle anti-PD-1 therapy (stage I-III) Patient tumor characteristics were obtained from the clinical record....